{"id":"erythromycin-ethyl-succinate","rwe":[{"pmid":"41408897","year":"2025","title":"Genotoxic Drug-Induced Hepatotoxicity: An In Silico Prediction Using Rattus norvegicus Microarray Gene Expression Data.","finding":"","journal":"Biotechnology and applied biochemistry","studyType":"Clinical Study"},{"pmid":"37998808","year":"2023","title":"Impact of Erythromycin as a Prokinetic on the Gut Microbiome in Children with Feeding Intolerance-A Pilot Study.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"15857350","year":"2005","title":"Does carboxymethylcellulose have a role in reducing time to full enteral feeds in preterm neonates?","finding":"","journal":"International journal of clinical practice","studyType":"Clinical Study"},{"pmid":"15610619","year":"2004","title":"Preparation and evaluation of a new erythromycin derivative -- erythromycin taurate.","finding":"","journal":"Acta pharmaceutica (Zagreb, Croatia)","studyType":"Clinical Study"},{"pmid":"11198727","year":"2000","title":"Can prophylactic oral erythromycin reduce time to full enteral feeds in preterm neonates?","finding":"","journal":"International journal of clinical practice","studyType":"Clinical Study"}],"tags":[{"label":"Macrolide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"For Suspension","category":"form"},{"label":"Granule","category":"form"},{"label":"Suspension","category":"form"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Bacterial pneumonia","category":"indication"},{"label":"Bacterial septicemia","category":"indication"},{"label":"Burn Wound Infections","category":"indication"},{"label":"Cholangitis","category":"indication"},{"label":"Hepatic coma","category":"indication"},{"label":"Infection of bone","category":"indication"},{"label":"Arbor Pharms Llc","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Protein Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":5741.799,"date":"","count":2871,"signal":"Drug hypersensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 2,871 times (LLR=5742)"},{"llr":352.455,"date":"","count":110,"signal":"International normalised ratio fluctuation","source":"DrugCentral FAERS","actionTaken":"Reported 110 times (LLR=352)"},{"llr":209.087,"date":"","count":64,"signal":"Bloody discharge","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=209)"},{"llr":158.802,"date":"","count":62,"signal":"Lyme disease","source":"DrugCentral FAERS","actionTaken":"Reported 62 times (LLR=159)"},{"llr":129.645,"date":"","count":122,"signal":"Abortion spontaneous","source":"DrugCentral FAERS","actionTaken":"Reported 122 times (LLR=130)"},{"llr":122.49,"date":"","count":53,"signal":"Seronegative arthritis","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=122)"},{"llr":114.942,"date":"","count":414,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 414 times (LLR=115)"},{"llr":89.919,"date":"","count":114,"signal":"Premature baby","source":"DrugCentral FAERS","actionTaken":"Reported 114 times (LLR=90)"},{"llr":85.271,"date":"","count":203,"signal":"Exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 203 times (LLR=85)"},{"llr":81.111,"date":"","count":96,"signal":"Toxic epidermal necrolysis","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=81)"},{"llr":77.284,"date":"","count":48,"signal":"Dislocation of vertebra","source":"DrugCentral FAERS","actionTaken":"Reported 48 times (LLR=77)"},{"llr":74.952,"date":"","count":232,"signal":"Maternal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 232 times (LLR=75)"},{"llr":73.478,"date":"","count":136,"signal":"Anaphylactic reaction","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=73)"},{"llr":65.81,"date":"","count":14,"signal":"Umbilical erythema","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=66)"},{"llr":64.708,"date":"","count":132,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 132 times (LLR=65)"}],"commonSideEffects":[],"contraindications":["Dehydration","Disorder of the 8th Cranial Nerve","Hypocalcemia","Infant Botulism","Kidney disease","Myasthenia gravis","Parkinsonism","Pregnancy, function","Tinnitus","Vertigo"],"specialPopulations":{"Pregnancy":"There is no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base by oral gavage at 350 mg/kg/day (approximately twice the maximum recommended human dose on body surface area) prior to and during mating, during gestation, and through weaning. No evidence of teratogenicity or embryotoxicity was observed when erythromycin base was given by oral gavage to pregnant rats and mice at 700 mg/kg/","Geriatric use":"Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced hearing loss. (See ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION).Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients. (See WARNINGS).Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See PRECAUTIONS Drug Interactions).","Paediatric use":"See INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections."}},"trials":[],"aliases":[],"company":"Arbor Pharms Llc","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$2.4310/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$887","description":"ERYTHROMYCIN 0.5% EYE OINTMENT","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Erythromycin ethyl succinate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:08:37.570855+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Erythromycin Ethyl Succinate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:08:45.859790+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:08:43.969454+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erythromycin ethyl succinate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:08:44.738818+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial 70S ribosome inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:08:45.859435+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL532/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:08:45.748016+00:00"}},"allNames":"eryped","offLabel":[],"synonyms":["erythromycin ethylsuccinate","erythromycin ethyl succinate","anamycin","arpimycin","eritrocina","erythrocin ethyl succinate"],"timeline":[{"date":"1965-04-02","type":"positive","source":"DrugCentral","milestone":"FDA approval (Arbor Pharms Llc)"}],"approvals":[{"date":"1965-04-02","orphan":false,"company":"ARBOR PHARMS LLC","regulator":"FDA"}],"brandName":"Eryped","ecosystem":[{"indication":"Bacterial pneumonia","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Bacterial septicemia","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"}],"globalPrevalence":null},{"indication":"Burn Wound Infections","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"gentamicin","slug":"gentamicin","company":"Schering"},{"name":"kanamycin","slug":"kanamycin","company":"Apothecon"},{"name":"mafenide","slug":"mafenide","company":"Mylan Institutional"}],"globalPrevalence":null},{"indication":"Cholangitis","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefazolin","slug":"cefazolin","company":"Glaxosmithkline"},{"name":"gentamicin","slug":"gentamicin","company":"Schering"}],"globalPrevalence":648000},{"indication":"Hepatic coma","otherDrugs":[{"name":"neomycin","slug":"neomycin","company":"Monarch Pharms"},{"name":"paromomycin","slug":"paromomycin","company":""}],"globalPrevalence":null},{"indication":"Infection of bone","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"},{"name":"cefalotin","slug":"cefalotin","company":"Lilly"}],"globalPrevalence":null},{"indication":"Infection of skin AND/OR subcutaneous tissue","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Infectious disease of abdomen","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"Macrolide","explanation":"","oneSentence":"","technicalDetail":"Erythromycin ethyl succinate binds to the 50S subunit of the bacterial ribosome, inhibiting the translocation step of protein synthesis and ultimately leading to the degradation of the bacterial mRNA and the inhibition of protein synthesis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Erythromycin","title":"Erythromycin","extract":"Erythromycin is an antibiotic used for the treatment of a number of bacterial infections. This includes respiratory tract infections, skin infections, chlamydia infections, pelvic inflammatory disease, and syphilis. It may also be used during pregnancy to prevent Group B streptococcal infection in the newborn, and to improve delayed stomach emptying. It can be given intravenously and by mouth. An eye ointment is routinely recommended after delivery to prevent eye infections in the newborn.","wiki_history":"== History ==\n\nIn 1952, Filipino scientist Abelardo B. Aguilar sent some soil samples to his employers at Eli Lilly and Company. Aguilar had managed to isolate erythromycin from the metabolic products of a strain of Streptomyces erythreus (designation changed to Saccharopolyspora erythraea) found in the samples. Aguilar received no further credit or compensation for his discovery.\n\nLilly filed for patent protection on the compound, which was granted in 1953. The product had been launched commercially in 1952 under the brand name \"Ilosone\" (after the Philippine province of Iloilo where Aguilar had collected the original soil samples). Erythromycin was also formerly called \"Ilotycin\".\n\nThe antibiotic clarithromycin was invented by scientists at the Japanese drug company Taisho Pharmaceutical in the 1970s as a result of their efforts to overcome the acid instability of erythromycin.","wiki_society_and_culture":"== Society and culture ==\n\n=== Economics ===\n\nIt is available as a generic medication.\n\nThe US price of erythromycin rose three times between 2010 and 2015, from 24 cents per 500mg tablet in 2010 to $8.96 in 2015. In 2017, a Kaiser Health News study found that the per-unit cost of dozens of generics doubled or even tripled from 2015 to 2016, increasing spending by the Medicaid program. Due to price increases by drug manufacturers, Medicaid paid on average $2,685,330 more for Erythromycin in 2016 compared to 2015 (not including rebates). In the US by 2018, generic drug prices had climbed another 5% on average.\n\nThe UK price listed in the BNF for erythromycin 500mg tablets was £36.40 for 100 tablets (36.4 pence each) . This price is not paid by NHS patients: there is no NHS prescription charge in Scotland, Wales, and Northern Ireland; while NHS patients in England without an exemption are liable for a flat rate prescription charge. , that charge was £9.90 for each prescribed medicine.\n\n===Brand names===\nBrand names include Robimycin, E-Mycin, E.E.S. Granules, E.E.S.-200, E.E.S.-400, E.E.S.-400 Filmtab, Erymax, Ery-Tab, Eryc, Ranbaxy, Erypar, EryPed, Eryped 200, Eryped 400, Erythrocin Stearate Filmtab, Erythrocot, E-Base, Erythroped, Ilosone, MY-E, Pediamycin, Zineryt, Abboticin, Abboticin-ES, Erycin, PCE Dispertab, Stiemycine, Acnasol, and Tiloryth."},"commercial":{"launchDate":"1965","_launchSource":"DrugCentral (FDA 1965-04-02, ARBOR PHARMS LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1051","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Erythromycin%20ethyl%20succinate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erythromycin ethyl succinate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Erythromycin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:11:06.362573","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:47.639751+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"erythromycin ethyl succinate","indications":{"approved":[{"name":"Bacterial pneumonia","source":"DrugCentral","snomedId":53084003,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Burn Wound Infections","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Cholangitis","source":"DrugCentral","snomedId":82403002,"regulator":"FDA","eligibility":"Adults and children over 6 months","prevalenceClass":"1-9 / 100 000","globalPrevalence":648000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (22245904[PMID])"},{"name":"Hepatic coma","source":"DrugCentral","snomedId":72836002,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Infectious disease of abdomen","source":"DrugCentral","snomedId":128070006,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Meningitis","source":"DrugCentral","snomedId":7180009,"regulator":"FDA","eligibility":"Adults and children over 6 months"},{"name":"Preoperative Bowel Preparation","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Urinary tract infectious disease","source":"DrugCentral","snomedId":68566005,"regulator":"FDA"}],"offLabel":[{"name":"Acute tuberculosis","source":"DrugCentral","drugName":"Erythromycin ethyl succinate","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Pulmonary tuberculosis","source":"DrugCentral","drugName":"Erythromycin ethyl succinate","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04235816","phase":"PHASE3","title":"Improving Care Through Azithromycin Research for Infants in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2021-03-15","conditions":["Child Mortality"],"enrollment":20560,"completionDate":"2026-04-30"},{"nctId":"NCT06082037","phase":"PHASE3","title":"A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-10-10","conditions":["Lung Transplant Rejection"],"enrollment":180,"completionDate":"2030-10-01"},{"nctId":"NCT04185402","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-29","conditions":["Trachoma"],"enrollment":3931,"completionDate":"2024-12-18"},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":["Mycobacterium Abscessus Pulmonary Disease","Mycobacterium Abscessus Infection","Non-Tuberculous Mycobacterial (NTM) Infections","Non-Tuberculous Mycobacteria Pulmonary Disease"],"enrollment":300,"completionDate":"2031-07"},{"nctId":"NCT04287049","phase":"PHASE2","title":"A Study of Standard Drugs for Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-02-24","conditions":["Mycobacterium Avium Complex"],"enrollment":10,"completionDate":"2025-03-21"},{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":["Severe Acute Malnutrition","HIV","Comorbidities and Coexisting Conditions","Child Malnutrition"],"enrollment":674,"completionDate":"2026-08-15"},{"nctId":"NCT01233297","phase":"PHASE2","title":"Antibiotic Treatment of Recurrent Episodes of Asthma in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Studies on Asthma in Childhood","startDate":"2010-11","conditions":["Childhood Asthma With Acute Exacerbation"],"enrollment":70,"completionDate":"2033-10"},{"nctId":"NCT06289647","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma B","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2024-10","conditions":["Trachoma"],"enrollment":0,"completionDate":"2029-08-31"},{"nctId":"NCT06488781","phase":"PHASE2","title":"Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2025-04-29","conditions":["Obesity in Pregnancy","Labor Complication"],"enrollment":787,"completionDate":"2028-12"},{"nctId":"NCT04069312","phase":"PHASE4","title":"Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-02-11","conditions":["Chronic Obstructive Pulmonary Disease Severe","Chronic Bronchitis"],"enrollment":1032,"completionDate":"2026-03-01"},{"nctId":"NCT07445282","phase":"PHASE4","title":"This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2025-05-14","conditions":["Extensively Drug-Resistant Typhoid Fever","Typhoid Fever","Salmonella Typhi Infection"],"enrollment":90,"completionDate":"2025-11-14"},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":["Interstitial Lung Disease"],"enrollment":30,"completionDate":"2027-10-01"},{"nctId":"NCT05949190","phase":"NA","title":"Improving Cognition and Gestational Duration With Targeted Nutrition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-08-18","conditions":["Malnutrition in Pregnancy","Preterm Birth","Child Development","Postpartum Depression","Antepartum Depression"],"enrollment":1660,"completionDate":"2026-10"},{"nctId":"NCT07439445","phase":"NA","title":"Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2026-02-24","conditions":["Helicobacter Pylori Infection"],"enrollment":70,"completionDate":"2027-02-13"},{"nctId":"NCT07436104","phase":"PHASE4","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01-01","conditions":["Hypertension (HTN)","Diarrhea","Pneumonia","Malaria Fever","COPD","Asthma (Diagnosis)","Diarrhea Chronic"],"enrollment":72564,"completionDate":"2023-08-31"},{"nctId":"NCT07433426","phase":"PHASE2","title":"The Impact of Shigellosis and Recommended Treatment in Children","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2026-03-15","conditions":["Diarrhea Infectious","Shigella","Growth & Development"],"enrollment":700,"completionDate":"2030-08"},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":["Helicobacter Pylori Infection"],"enrollment":337,"completionDate":"2024-12-03"},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":["HELICOBACTER PYLORI INFECTIONS","Helicobacter Infection","Helicobacter Pylori Gastrointestinal Tract Infection","Helicobacter Pylori Infected Patients"],"enrollment":66,"completionDate":"2026-12-20"},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":["Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI"],"enrollment":1600,"completionDate":"2027-07-31"},{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":["Bronchiolitis Obliterans Syndrome","Bronchiolitis Obliterans","Lung Diseases","Chronic Graft Versus Host Disease"],"enrollment":45,"completionDate":"2027-12-31"},{"nctId":"NCT07394725","phase":"PHASE1","title":"Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management","status":"COMPLETED","sponsor":"District Headquarters Teaching Hospital Sahiwal","startDate":"2024-04-01","conditions":["Pre-term Premature Rupture of Membranes"],"enrollment":250,"completionDate":"2025-03-31"},{"nctId":"NCT04677569","phase":"PHASE3","title":"Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2021-04-01","conditions":["Mycobacterium Infections, Nontuberculous"],"enrollment":425,"completionDate":"2026-01-15"},{"nctId":"NCT07384793","phase":"PHASE4","title":"Comparison of Efficacy of Azithromycin Alone vs Combination of Azithromycin and Probiotics in Management of Mild to Moderate Acne Vulgaris","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hayatabad Medical Complex","startDate":"2025-10-12","conditions":["Acne Vulgaris II or III Degree"],"enrollment":60,"completionDate":"2026-04"},{"nctId":"NCT06605118","phase":"PHASE3","title":"Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial","status":"RECRUITING","sponsor":"The George Washington University Biostatistics Center","startDate":"2024-11-06","conditions":["Obstetrical Complications","Labor and Delivery Complication","Cesarean Delivery"],"enrollment":8000,"completionDate":"2027-11-30"},{"nctId":"NCT06837259","phase":"PHASE1","title":"A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-03-19","conditions":["Healthy Adults"],"enrollment":26,"completionDate":"2025-06-11"},{"nctId":"NCT03672630","phase":"PHASE2,PHASE3","title":"Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease","status":"COMPLETED","sponsor":"Kevin Winthrop","startDate":"2019-02-22","conditions":["Mycobacterium Avium Complex","Nontuberculous Mycobacterium Infection"],"enrollment":474,"completionDate":"2026-01-08"},{"nctId":"NCT04481555","phase":"PHASE4","title":"Eosinophil-guided Reduction of Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2021-06-28","conditions":["COPD","Inhaled Corticosteroid","Azithromycin","COPD Exacerbation","Pneumonia"],"enrollment":444,"completionDate":"2025-11-19"},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":["Preterm Premature Rupture of Membrane","Pregnancy, High Risk","Preterm Birth"],"enrollment":56,"completionDate":"2026-12"},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":["Chemotherapy Effect"],"enrollment":198,"completionDate":"2027-07-31"},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":["Chronic GVHD"],"enrollment":10,"completionDate":"2024-10-01"},{"nctId":"NCT06077916","phase":"NA","title":"Gastric CLEANsing by Intravenous AZithromycin in Urgent Endoscopy","status":"COMPLETED","sponsor":"Clinical Hospital Colentina","startDate":"2023-10-01","conditions":["Upper Gastrointestinal Bleeding"],"enrollment":224,"completionDate":"2025-11-01"},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":["Helicobacter Pylori Eradication"],"enrollment":390,"completionDate":"2026-12-31"},{"nctId":"NCT04349826","phase":"PHASE4","title":"The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2021-05-23","conditions":["Typhoid Fever"],"enrollment":2150,"completionDate":"2025-12-31"},{"nctId":"NCT07341100","phase":"PHASE2","title":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2026-01","conditions":["Ovarian Epithelial Cancer"],"enrollment":20,"completionDate":"2028-06"},{"nctId":"NCT05842681","phase":"NA","title":"Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Assiut University","startDate":"2023-06-01","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":30,"completionDate":"2026-04-30"},{"nctId":"NCT03083197","phase":"PHASE4","title":"Scrub Typhus Antibiotic Resistance Trial","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2017-10-15","conditions":["Scrub Typhus"],"enrollment":177,"completionDate":"2026-10"},{"nctId":"NCT07316959","phase":"NA","title":"Efficacy of Long-Term Low Dose Macrolide Therapy in Preventing Early Recurrence of Nasal Polyps After Endoscopic Sinus Surgery","status":"COMPLETED","sponsor":"Fatima Jinnah Medical University","startDate":"2025-01-01","conditions":["Chronic Rhinosinusitis With Nasal Polyps"],"enrollment":100,"completionDate":"2025-06-15"},{"nctId":"NCT07320612","phase":"PHASE1","title":"Efficacy And Safety Of Azithromycin To Achieve Remissionin In Children With Steroid Sensitive Nephrotic Syndrome","status":"COMPLETED","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2025-03-08","conditions":["Nephrotic Syndrome"],"enrollment":160,"completionDate":"2025-10-08"},{"nctId":"NCT07294846","phase":"PHASE1","title":"Drug Interaction Study on Linaprazan Glurate Capsules","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2025-09-08","conditions":["Healthy Volunteers","Patients"],"enrollment":56,"completionDate":"2025-12-15"},{"nctId":"NCT07314281","phase":"PHASE4","title":"Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever","status":"RECRUITING","sponsor":"Indus Hospital and Health Network","startDate":"2025-04-22","conditions":["Enteric Fever"],"enrollment":40,"completionDate":"2025-12-31"},{"nctId":"NCT07306234","phase":"PHASE4","title":"Doxycycline vs. Macrolide for MRMP (DOMINO)","status":"NOT_YET_RECRUITING","sponsor":"Young June Choe","startDate":"2026-03-01","conditions":["Mycoplasma Pneumoniae","Mycoplasma Pneumoniae Pneumonia"],"enrollment":208,"completionDate":"2029-02-28"},{"nctId":"NCT07275827","phase":"PHASE3","title":"Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":["HELICOBACTER PYLORI INFECTIONS"],"enrollment":88,"completionDate":"2026-10"},{"nctId":"NCT04630145","phase":"PHASE2,PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":["Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)"],"enrollment":129,"completionDate":"2025-11-14"},{"nctId":"NCT02343042","phase":"PHASE1,PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":["Multiple Myeloma"],"enrollment":300,"completionDate":"2027-04"},{"nctId":"NCT06223828","phase":"PHASE2,PHASE3","title":"Azithromycin for Critical Asthma - Pediatrics","status":"RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2024-04-02","conditions":["Pediatric Asthma","Critical Illness"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT05926804","phase":"NA","title":"A \"Screen and Treat\" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile","status":"RECRUITING","sponsor":"Miguel O'Ryan Gallardo","startDate":"2022-08-02","conditions":["Helicobacter Pylori Infection"],"enrollment":500,"completionDate":"2027-08"},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":["Community-acquired Pneumonia"],"enrollment":330,"completionDate":"2026-07-30"},{"nctId":"NCT02754583","phase":"PHASE3","title":"Sanitation, Water, and Instruction in Face-washing for Trachoma I/II","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-12-05","conditions":["Trachoma"],"enrollment":47605,"completionDate":"2024-12-31"},{"nctId":"NCT06751121","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-02-06","conditions":["Helicobacter Pylori Infection","Helicobacter Pylori Infected Patients","Helicobacter Pylori Infected Subjects"],"enrollment":461,"completionDate":"2025-04-24"},{"nctId":"NCT04344379","phase":"PHASE3","title":"Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-17","conditions":["SARS-CoV-2 Infection"],"enrollment":122,"completionDate":"2020-06-18"},{"nctId":"NCT01298336","phase":"PHASE3","title":"Treatment of Mycobacterium Xenopi Pulmonary Infection","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-03-02","conditions":["Atypical; Mycobacterium, Pulmonary, Tuberculous"],"enrollment":92,"completionDate":"2019-03"},{"nctId":"NCT03236987","phase":"PHASE3","title":"CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2018-02-05","conditions":["Lung Infection","MAC Lung Disease"],"enrollment":424,"completionDate":"2029-02-05"},{"nctId":"NCT06618534","phase":"PHASE2","title":"Azithromycin for Meningococcal Carriage","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-11-12","conditions":["Meningococcal Infections"],"enrollment":1120,"completionDate":"2026-05"},{"nctId":"NCT03250975","phase":"PHASE1,PHASE2","title":"Incidence of Acute Laryngeal Injury Following Endotracheal Intubation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2017-08-19","conditions":["Intubation Complication"],"enrollment":64,"completionDate":"2026-12-30"},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":["Asthma","Asthma Attack","Asthma Exacerbations"],"enrollment":3200,"completionDate":"2029-11-15"},{"nctId":"NCT03335072","phase":"PHASE4","title":"Kebele Elimination of Trachoma for Ocular Health","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-02-07","conditions":["Trachoma"],"enrollment":320000,"completionDate":"2028-03-01"},{"nctId":"NCT06010719","phase":"PHASE4","title":"Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-23","conditions":["Malnutrition, Child","Severe Acute Malnutrition"],"enrollment":3000,"completionDate":"2028-12-29"},{"nctId":"NCT06948747","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":["Healthy Participants"],"enrollment":49,"completionDate":"2025-10-03"},{"nctId":"NCT07213765","phase":"PHASE4","title":"Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease","status":"RECRUITING","sponsor":"Bin Cao","startDate":"2025-07-24","conditions":["Mycobacterium Avium Complex Pulmonary Disease"],"enrollment":188,"completionDate":"2028-12-31"},{"nctId":"NCT07211880","phase":"NA","title":"Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study","status":"COMPLETED","sponsor":"Zero Helicobacter IGAN Network","startDate":"2019-12-05","conditions":["H.Pylori","Gastric Cancer","H Pylori Eradication"],"enrollment":1043,"completionDate":"2023-03-21"},{"nctId":"NCT07164131","phase":"PHASE4","title":"Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-09-15","conditions":["Community-acquired Pneumonia"],"enrollment":1120,"completionDate":"2031-09-01"},{"nctId":"NCT03959527","phase":"PHASE3","title":"Zoliflodacin in Uncomplicated Gonorrhoea","status":"COMPLETED","sponsor":"Global Antibiotics Research and Development Partnership","startDate":"2019-11-06","conditions":["Gonorrhea"],"enrollment":1011,"completionDate":"2023-09-18"},{"nctId":"NCT04302324","phase":"PHASE2","title":"A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-10-28","conditions":["Multiple Myeloma","Refractory Multiple Myeloma","Relapse Multiple Myeloma"],"enrollment":9,"completionDate":"2027-12-28"},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":["Helicobacter Pylori Infection"],"enrollment":450,"completionDate":"2025-12"},{"nctId":"NCT06273891","phase":"PHASE3","title":"Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2024-03-08","conditions":["Premature Rupture of Membrane"],"enrollment":140,"completionDate":"2026-10-01"},{"nctId":"NCT06917872","phase":"PHASE1","title":"A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-04-29","conditions":["Healthy"],"enrollment":20,"completionDate":"2025-09-09"},{"nctId":"NCT06543290","phase":"PHASE1","title":"Azithromycin Before Induction","status":"RECRUITING","sponsor":"Arrowhead Regional Medical Center","startDate":"2023-08-07","conditions":["Infections"],"enrollment":400,"completionDate":"2026-08-07"},{"nctId":"NCT01745588","phase":"PHASE2","title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":["Multiple Myeloma"],"enrollment":23,"completionDate":"2025-09-03"},{"nctId":"NCT02707042","phase":"PHASE1","title":"Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-22","conditions":["Normal Physiology","Healthy"],"enrollment":108,"completionDate":"2025-05-15"},{"nctId":"NCT01559935","phase":"PHASE2","title":"Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-04-19","conditions":["Multiple Myeloma"],"enrollment":74,"completionDate":"2027-03-01"},{"nctId":"NCT03925480","phase":"PHASE3","title":"Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2019-07-01","conditions":["Bacterial Infections"],"enrollment":2110,"completionDate":"2023-02-28"},{"nctId":"NCT05580666","phase":"PHASE3","title":"Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2023-05-08","conditions":["HIV Disease Progression"],"enrollment":8000,"completionDate":"2029-05-31"},{"nctId":"NCT05157685","phase":"PHASE3","title":"Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2022-11-21","conditions":["Sinusitis, Chronic","Sinus Infection Chronic"],"enrollment":230,"completionDate":"2027-11-21"},{"nctId":"NCT07148622","phase":"NA","title":"Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-10-01","conditions":["Preterm Premature Rupture of Membranes (PPROM)","Prophylaxis","Perinatal Outcomes"],"enrollment":40,"completionDate":"2025-08-10"},{"nctId":"NCT07144657","phase":"PHASE2","title":"Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-01","conditions":["MALT Lymphoma of Stomach"],"enrollment":40,"completionDate":"2030-12-31"},{"nctId":"NCT07040787","phase":"PHASE1","title":"Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2025-07-08","conditions":["Complement Mediated Glomerular Diseases","Hemolytic Anemia"],"enrollment":36,"completionDate":"2025-08-17"},{"nctId":"NCT03273296","phase":"PHASE4","title":"Effect of Antibiotics on Gut Microbiome and Plasma Metabolome","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2017-10-15","conditions":["Microbial Colonization"],"enrollment":39,"completionDate":"2017-12-15"},{"nctId":"NCT05121974","phase":"PHASE2","title":"Tebipenem Trial in Children With Shigellosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-08-18","conditions":["Shigellosis"],"enrollment":132,"completionDate":"2026-08-17"},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":["H.Pylori Infection"],"enrollment":700,"completionDate":"2024-03-26"},{"nctId":"NCT04921943","phase":"PHASE4","title":"Hypertonic Saline for MAC","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2021-05-18","conditions":["Nontuberculous Mycobacterial Lung Disease","Nontuberculous Mycobacterium Infection"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":["Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer"],"enrollment":400,"completionDate":"2025-11-01"},{"nctId":"NCT07115173","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-12-01","conditions":["Helicobacter Infection"],"enrollment":103,"completionDate":"2027-12-31"},{"nctId":"NCT04310930","phase":"PHASE2,PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":["Pulmonary Disease Due to Mycobacteria (Diagnosis)"],"enrollment":300,"completionDate":"2030-06-30"},{"nctId":"NCT03953118","phase":"PHASE4","title":"Azithromycin for Meibomian Gland Disease","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2019-09-01","conditions":["Dry Eye","Neuropathic Eye Pain","Ocular Microbiome","Depression, Anxiety"],"enrollment":2,"completionDate":"2021-07-01"},{"nctId":"NCT07086937","phase":"NA","title":"Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-01-01","conditions":["Helicobacter Pylori Infection"],"enrollment":66,"completionDate":"2025-06-30"},{"nctId":"NCT05961189","phase":"EARLY_PHASE1","title":"Influence of Short-Term Antibiotic Therapy on Exercise","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-09-01","conditions":["Gastrointestinal Microbiome","Exercise"],"enrollment":40,"completionDate":"2025-12-01"},{"nctId":"NCT03523156","phase":"PHASE4","title":"Trachoma Elimination Study by Focused Antibiotic (TESFA)","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2025-06","conditions":["Trachoma"],"enrollment":0,"completionDate":"2027-04"},{"nctId":"NCT04026958","phase":"PHASE2","title":"Clarithromycin Mechanisms in Hypersomnia Syndromes","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-04","conditions":["Narcolepsy Without Cataplexy","Idiopathic Hypersomnia","Narcolepsy With Cataplexy"],"enrollment":83,"completionDate":"2025-06-18"},{"nctId":"NCT07063082","phase":"NA","title":"Efficacy Of Erythromycin Phonophoresis on Chronic Rhinosinusitis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-07-07","conditions":["Chronic Rhinosinusitis"],"enrollment":90,"completionDate":"2025-09-15"},{"nctId":"NCT07064278","phase":"NA","title":"Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children","status":"COMPLETED","sponsor":"Children's Hospital of Hebei Province","startDate":"2022-12-01","conditions":["Refractory Mycoplasma Pneumoniae Pneumonia"],"enrollment":260,"completionDate":"2024-05-31"},{"nctId":"NCT06804096","phase":"PHASE4","title":"Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","status":"RECRUITING","sponsor":"Dr. Md. Alimur Reza","startDate":"2025-02-20","conditions":["Pneumonia, Community-Acquired","Bacterial Pneumonia"],"enrollment":160,"completionDate":"2025-12-01"},{"nctId":"NCT04326478","phase":"PHASE2","title":"Single Dose Azithromycin to Prevent Cholera in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-10-31","conditions":["Cholera"],"enrollment":920,"completionDate":"2026-05-31"},{"nctId":"NCT06514274","phase":"PHASE4","title":"Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-09-20","conditions":["Helicobacter Pylori Infection","Chronic Gastritis"],"enrollment":558,"completionDate":"2025-06-25"},{"nctId":"NCT06523764","phase":"PHASE4","title":"Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-11-11","conditions":["Helicobacter Pylori Infection Chronic Gastrit"],"enrollment":208,"completionDate":"2025-10-01"},{"nctId":"NCT05742568","phase":"PHASE4","title":"Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-12-01","conditions":["Gastritis","Dyspepsia","Helicobacter Pylori Infection","Gastric Cancer","Peptic Ulcer"],"enrollment":124,"completionDate":"2024-03-10"},{"nctId":"NCT06005714","phase":"PHASE1","title":"Effect of Pharmacokinetics in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2023-08-15","conditions":["The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects"],"enrollment":36,"completionDate":"2023-10-31"},{"nctId":"NCT04186247","phase":"PHASE2","title":"Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-08-13","conditions":["Crohn Disease","Pediatric Crohns Disease"],"enrollment":13,"completionDate":"2023-12-31"},{"nctId":"NCT07040839","phase":"PHASE4","title":"Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-07","conditions":["H Pylori"],"enrollment":128,"completionDate":"2026-02"},{"nctId":"NCT06358872","phase":"PHASE4","title":"Azithromycin for Child Survival in Niger II","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-04-29","conditions":["Mortality","Antimicrobial Resistance"],"enrollment":3300000,"completionDate":"2028-04-29"},{"nctId":"NCT07021729","phase":"PHASE4","title":"Comparison of Two Treatment Regimens of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-12","conditions":["Helicobacter Pylori Infection"],"enrollment":156,"completionDate":"2026-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"For Suspension, Granule, Suspension, Tablet","formulations":[{"form":"FOR SUSPENSION","route":"ORAL","productName":"Erythromycin ethylsuccinate"},{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","productName":"ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL"},{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","productName":"Erythromycin Ethylsuccinate"},{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","productName":"E.E.S"},{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","productName":"Erythromycin Ethylsuccinate"},{"form":"SUSPENSION","route":"ORAL","productName":"Erythromycin Ethylsuccinate"},{"form":"SUSPENSION","route":"ORAL","productName":"ERYTHROMYCIN ETHYLSUCCINATE"},{"form":"SUSPENSION","route":"ORAL","productName":"Ery-Ped"},{"form":"TABLET","route":"ORAL","productName":"E.E.S 400"},{"form":"TABLET","route":"ORAL","productName":"ERYTHROMYCIN ETHYLSUCCINATE"},{"form":"TABLET","route":"ORAL","productName":"Erythromycin Ethylsuccinate"}]},"crossReferences":{"NUI":"N0000145973","MMSL":"33314","NDDF":"002755","UNII":"1014KSJ86F","VUID":"4017592","CHEBI":"CHEBI:31555","VANDF":"4017592","INN_ID":"39","RXNORM":"151373","UMLSCUI":"C0014810","chemblId":"CHEMBL532","ChEMBL_ID":"CHEMBL1200688","DRUGBANK_ID":"DB00199","PUBCHEM_CID":"443953","SNOMEDCT_US":"12578001","MESH_DESCRIPTOR_UI":"D015643"},"formularyStatus":[],"originalProduct":{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","company":"Arbor Pharmaceuticals, Inc.","brandName":"E.E.S","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1965-","companyName":"Arbor Pharms Llc","relationship":"Original Developer"}],"publicationCount":38,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"originalDeveloper":"Arbor Pharms Llc","recentPublications":[{"date":"2025 Dec 17","pmid":"41408897","title":"Genotoxic Drug-Induced Hepatotoxicity: An In Silico Prediction Using Rattus norvegicus Microarray Gene Expression Data.","journal":"Biotechnology and applied biochemistry"},{"date":"2023 Nov 8","pmid":"37998808","title":"Impact of Erythromycin as a Prokinetic on the Gut Microbiome in Children with Feeding Intolerance-A Pilot Study.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2005 May","pmid":"15857350","title":"Does carboxymethylcellulose have a role in reducing time to full enteral feeds in preterm neonates?","journal":"International journal of clinical practice"},{"date":"2004 Sep","pmid":"15610619","title":"Preparation and evaluation of a new erythromycin derivative -- erythromycin taurate.","journal":"Acta pharmaceutica (Zagreb, Croatia)"},{"date":"2000 Oct","pmid":"11198727","title":"Can prophylactic oral erythromycin reduce time to full enteral feeds in preterm neonates?","journal":"International journal of clinical practice"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Arbor Pharms Llc","companyId":"arbor-pharms-llc","modality":"Small molecule","firstApprovalDate":"1965","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1965-04-02T00:00:00.000Z","mah":"ARBOR PHARMS LLC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1965-04-02T00:00:00.000Z","mah":"ARBOR PHARMS LLC","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1965-04-02T00:00:00.000Z","mah":"ARBOR PHARMS LLC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1965-04-02T00:00:00.000Z","mah":"ARBOR PHARMS LLC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1965-04-02T00:00:00.000Z","mah":"ARBOR PHARMS LLC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1965-04-02T00:00:00.000Z","mah":"ARBOR PHARMS LLC","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"887.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:47.639751+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}